| [1] | "dehydroepiandrosterone,vaginal atrophy" [DB/OL]. Available: https://clinicaltrials.gov/ct2/results?term=vaginal+atrophy&Search=Search. |
| [2] | 牛治欣. 阴道萎缩的诊断及治疗进展[J]. 职业与健康, 2007,23(17):1557-1558. |
| [3] | 刘晓霞. 女性围绝经期健康大讲堂(之十三) 女性更年期泌尿生殖系统疾病治疗组合方案[J]. 首都医药, 2012:51-52. |
| [4] | van Geelen JM, van de Weifer PH, Amolds HT. Urogenital symptoms and resulting discomfort in non-institutionalixed Dutch women aged 50-75 years[J]. Iht Urogynecol J Pelvic Floor Dysfunct, 2000,11(1):9-14. |
| [5] | 曹江霞,周 燕. 不同分娩方式对围绝经期女性盆底功能影响的研究[J]. 中国妇幼保健, 2010,25(16):4504-4506. |
| [6] | 王俊玲.女性更年期泌尿生殖系统症状的激素替代治疗研究[J/OL]. 心理医生,2012(5): 110-111. http://med.wanfangdata.com.cn/Paper/Detail/PeriodicalPaper_xlys-xbyb201205112. |
| [7] | 王丽鸽,崔丽霞. 普罗雌烯治疗绝经后妇女萎缩性阴道炎的有效性及安全性的临床评估[J]. 中国妇幼保健,2007,22(13):1849-1850. |
| [8] | Labrie F, Luu-The V, Bélanger A, et al. Is dehydroepiandrosterone a hormone?[J]. J Endocrinol, 2005,187(2):169-196. |
| [9] | Labrie F, Bé langer A, Luu-The V, et al.DHEA and the intracrine formation of androgens an estrogens in peripheral target tissues: its role during aging[J]. Steroids,1998,63(5-6):322-328. |
| [10] | Labrie F, Diamond P, Cusan L, et al. Effect of 12-month dehydroepiandrosterone replacement therapy on bone, vagina, and endometrium in postmenopausal women[J]. J Clin Endocrinol Metab, 1997,82 (10):3498-3505. |
| [11] | Labrie F, Cusan L, Gomez JL, et al. Effect of intravaginal DHEA on serum DHEA and eleven of its metabolites in postmenopausal women[J]. J Steroid Biochem Mol Biol, 2008,111(3-5):178-194. |
| [12] | Ke Y, Labrie F, Gonthier R, et al. Serum levels of sex steroids and metabolites following 12 weeks of intravaginal 0.50% DHEA administration[J]. J Steroid Biochem Mol Biol, 2015,154:186-196. |
| [13] | Labrie F, Derogatis L, Archer DF, et al. Effect of intravaginal prasterone on sexual dysfunction in postmenopausal women with vulvovaginal atrophy[J]. J Sex Med, 2015,12(12):2401-2412. |
| [14] | Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause[J]. Menopause, 2016,23(3):243-256. |
| [15] | Labrie F, Montesino M, Archer DF, et al. Influence of treatment of vulvovaginal atrophy with intravaginal prasterone on the male partner[J]. Climacteric, 2015,18(6):817-825. |